vs

Side-by-side financial comparison of ENNIS, INC. (EBF) and NEOGENOMICS INC (NEO). Click either name above to swap in a different company.

NEOGENOMICS INC is the larger business by last-quarter revenue ($186.7M vs $100.2M, roughly 1.9× ENNIS, INC.). ENNIS, INC. runs the higher net margin — 10.8% vs -57.9%, a 68.7% gap on every dollar of revenue. On growth, NEOGENOMICS INC posted the faster year-over-year revenue change (11.1% vs 0.4%). Over the past eight quarters, NEOGENOMICS INC's revenue compounded faster (6.5% CAGR vs 1.4%).

ENNIS, INC. (ticker EBF) is a leading North American provider of printed business products and related services. Its offerings include custom business forms, pressure-sensitive labels, marketing collateral, promotional items, and branded packaging, serving clients across retail, healthcare, financial services, and small business segments.

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.

EBF vs NEO — Head-to-Head

Bigger by revenue
NEO
NEO
1.9× larger
NEO
$186.7M
$100.2M
EBF
Growing faster (revenue YoY)
NEO
NEO
+10.7% gap
NEO
11.1%
0.4%
EBF
Higher net margin
EBF
EBF
68.7% more per $
EBF
10.8%
-57.9%
NEO
Faster 2-yr revenue CAGR
NEO
NEO
Annualised
NEO
6.5%
1.4%
EBF

Income Statement — Q3 FY2026 vs Q1 FY2026

Metric
EBF
EBF
NEO
NEO
Revenue
$100.2M
$186.7M
Net Profit
$10.8M
$-108.0M
Gross Margin
31.9%
43.3%
Operating Margin
15.0%
46.9%
Net Margin
10.8%
-57.9%
Revenue YoY
0.4%
11.1%
Net Profit YoY
6.1%
42.0%
EPS (diluted)
$0.42
$-0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EBF
EBF
NEO
NEO
Q1 26
$186.7M
Q4 25
$100.2M
$190.2M
Q3 25
$98.7M
$187.8M
Q2 25
$97.2M
$181.3M
Q1 25
$92.7M
$168.0M
Q4 24
$99.8M
$172.0M
Q3 24
$99.0M
$167.8M
Q2 24
$103.1M
$164.5M
Net Profit
EBF
EBF
NEO
NEO
Q1 26
$-108.0M
Q4 25
$10.8M
Q3 25
$13.2M
$-27.1M
Q2 25
$9.8M
$-45.1M
Q1 25
$9.0M
$-25.9M
Q4 24
$10.2M
Q3 24
$10.3M
$-17.7M
Q2 24
$10.7M
$-18.6M
Gross Margin
EBF
EBF
NEO
NEO
Q1 26
43.3%
Q4 25
31.9%
43.8%
Q3 25
30.5%
42.8%
Q2 25
31.1%
42.6%
Q1 25
29.5%
43.6%
Q4 24
29.3%
44.9%
Q3 24
30.1%
44.6%
Q2 24
30.0%
44.1%
Operating Margin
EBF
EBF
NEO
NEO
Q1 26
46.9%
Q4 25
15.0%
-7.1%
Q3 25
12.5%
-14.4%
Q2 25
13.7%
-26.3%
Q1 25
13.0%
-16.6%
Q4 24
13.1%
-10.7%
Q3 24
13.3%
-12.6%
Q2 24
13.3%
-13.3%
Net Margin
EBF
EBF
NEO
NEO
Q1 26
-57.9%
Q4 25
10.8%
Q3 25
13.3%
-14.4%
Q2 25
10.1%
-24.9%
Q1 25
9.7%
-15.4%
Q4 24
10.2%
Q3 24
10.4%
-10.5%
Q2 24
10.4%
-11.3%
EPS (diluted)
EBF
EBF
NEO
NEO
Q1 26
$-0.13
Q4 25
$0.42
Q3 25
$0.51
Q2 25
$0.38
Q1 25
$0.34
Q4 24
$0.39
Q3 24
$0.40
Q2 24
$0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EBF
EBF
NEO
NEO
Cash + ST InvestmentsLiquidity on hand
$31.3M
$146.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$304.8M
$828.8M
Total Assets
$354.3M
$1.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EBF
EBF
NEO
NEO
Q1 26
$146.1M
Q4 25
$31.3M
$159.6M
Q3 25
$31.9M
$164.1M
Q2 25
$32.6M
$154.7M
Q1 25
$72.5M
$346.2M
Q4 24
$68.6M
$367.0M
Q3 24
$122.6M
$362.0M
Q2 24
$123.7M
$355.1M
Total Debt
EBF
EBF
NEO
NEO
Q1 26
Q4 25
$341.9M
Q3 25
Q2 25
Q1 25
Q4 24
$541.1M
Q3 24
Q2 24
Stockholders' Equity
EBF
EBF
NEO
NEO
Q1 26
$828.8M
Q4 25
$304.8M
$836.6M
Q3 25
$305.4M
$838.3M
Q2 25
$301.2M
$854.0M
Q1 25
$302.0M
$888.3M
Q4 24
$297.7M
$902.3M
Q3 24
$358.4M
$908.2M
Q2 24
$354.4M
$915.9M
Total Assets
EBF
EBF
NEO
NEO
Q1 26
$1.3B
Q4 25
$354.3M
$1.4B
Q3 25
$361.8M
$1.4B
Q2 25
$361.7M
$1.4B
Q1 25
$348.9M
$1.6B
Q4 24
$346.1M
$1.6B
Q3 24
$406.8M
$1.6B
Q2 24
$406.2M
$1.6B
Debt / Equity
EBF
EBF
NEO
NEO
Q1 26
Q4 25
0.41×
Q3 25
Q2 25
Q1 25
Q4 24
0.60×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EBF
EBF
NEO
NEO
Operating Cash FlowLast quarter
$16.4M
$-8.1M
Free Cash FlowOCF − Capex
$15.7M
FCF MarginFCF / Revenue
15.7%
Capex IntensityCapex / Revenue
0.7%
Cash ConversionOCF / Net Profit
1.52×
TTM Free Cash FlowTrailing 4 quarters
$42.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EBF
EBF
NEO
NEO
Q1 26
$-8.1M
Q4 25
$16.4M
$1.3M
Q3 25
$10.5M
$8.9M
Q2 25
$8.0M
$20.3M
Q1 25
$12.8M
$-25.3M
Q4 24
$18.2M
$9.8M
Q3 24
$11.8M
$9.2M
Q2 24
$23.1M
$13.9M
Free Cash Flow
EBF
EBF
NEO
NEO
Q1 26
Q4 25
$15.7M
$-6.5M
Q3 25
$9.0M
$570.0K
Q2 25
$6.6M
$14.0M
Q1 25
$11.1M
$-29.8M
Q4 24
$17.5M
$-1.8M
Q3 24
$10.7M
$-1.6M
Q2 24
$20.6M
$814.0K
FCF Margin
EBF
EBF
NEO
NEO
Q1 26
Q4 25
15.7%
-3.4%
Q3 25
9.2%
0.3%
Q2 25
6.8%
7.7%
Q1 25
12.0%
-17.8%
Q4 24
17.6%
-1.0%
Q3 24
10.8%
-0.9%
Q2 24
20.0%
0.5%
Capex Intensity
EBF
EBF
NEO
NEO
Q1 26
Q4 25
0.7%
4.1%
Q3 25
1.4%
4.4%
Q2 25
1.4%
3.5%
Q1 25
1.8%
2.7%
Q4 24
0.6%
6.7%
Q3 24
1.1%
6.4%
Q2 24
2.4%
8.0%
Cash Conversion
EBF
EBF
NEO
NEO
Q1 26
Q4 25
1.52×
Q3 25
0.80×
Q2 25
0.81×
Q1 25
1.41×
Q4 24
1.78×
Q3 24
1.15×
Q2 24
2.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons